Table 2.

Correlations between CD20 expression and disease features of chronic lymphocytic leukemia

Parameter	CD20%			CD20 MFI
	No. of cases	Median (P5–P95)	P‐value	No. of cases	Median (P5–P95)	P‐value
Gender (n = 172)
Male	113	96.22 (37.26–100)	0.30	113	863.44 (88.78–4451.36)	0.20
Female	59	100 (51.10–100)		59	588.52 (81.05–3466.56)
Age (n = 172)
≥60 years	109	97.71 (46.55–100)	0.88	109	952.26 (99.05–3933.46)	0.06
<60 years	63	98.40 (36.84–100)		63	524.15 (53.50–4477.11)
Binet stage (n = 172)
A	83	97.71 (53.70–100)	0.52	83	731.64 (77.23–4630.52)	0.48
B	36	91.90 (31.87–100)		36	547.28 (84.81–3250.45)
C	53	100 (27.60–100)		53	833.09 (159.80–4044.24)
CD38 (n = 169)
Positive	50	98.73 (56.09–100)	1.00	50	733.38 (92.45–3933.07)	0.60
Negative	119	97.71 (37.97–100)		119	731.64 (82.81–3915.94)
ZAP‐70 (n = 167)
Positive	44	97.08 (52.40–100)	0.86	44	598.21 (97.36–3935.30)	0.84
Negative	123	97.46 (39.00–100)		123	751.56 (96.03–3857.34)
IGHV (n = 153)
Unmutated	52	90.48 (3.03–100)	<0.001	52	480.71 (78.74–3569.62)	0.19
Mutated	101	100 (50.99–100)		101	751.56 (83.86–4666.35)
p53 mutation status (n = 156)
Presence	28	96.61 (3.97–100)	0.36	28	469.89 (145.07–4737.80)	0.73
Absence	128	98.29 (51.92–100)		128	731.45 (81.84–3933.82)
Treatment (n = 172)
No	91	100 (56.42–100)	0.10	91	930.26 (79.14–4324.41)	0.30
Yes	81	95.06 (37.56–100)		81	559.89 (107.62–3533.46)
Cytogenetics (n = 172)
del(17p13) or del(11q22.3)	45	98.96 (3.78–100)	0.59	45	548.16 (93.49–6766.42)	0.21
del(13q14) as the sole abnormality	9	88.83 (65.93–100)		9	313.30 (82.81–3199.19)
Others	118	97.82 (44.60–100)		118	818.77 (90.59–3930.09)

IGHV, variable region of immunoglobulin genes; MFI, mean fluorescence intensity; ZAP‐70, zeta‐associated protein‐70.